Patient’s adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?

Table 3 Hospitalization rates for BPH and BPH-related surgery

Outcomes	Overall		Mono alpha		Mono 5ARI		CT
Outcomes	Events	IR (95 % CI)	Events	IR (95 % CI)	Events	IR (95 % CI)	Events	IR (95 % CI)
Hospitalization for BPH (non surgical reasons)	989	9.04 (8.49;9.62)	918	9.58 (8.98;10.22)	34	3.77 (2.69;5.27)	37	8.10 (5.87;11.18)
BPH - related surgery	1393	12.60 (11.96;13.28)	1351	13.96 (13.23;14.72)	23	2.54 (1.69;3.82)	19	4.08 (2.60;6.40)

Legend: AB: Alpha-blocker monotherapy; 5ARI; 5-alpha reductase inhibitors monotherapy; CT: Combination Therapy; IR: incidence rate for 1000 person-years

ISSN: 1471-2490